Cardiol Therapeutics (CRDL) Expected to Announce Earnings on Thursday

Cardiol Therapeutics (NASDAQ:CRDL) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Cardiol Therapeutics to post earnings of ($0.06) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

Cardiol Therapeutics (NASDAQ:CRDL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. On average, analysts expect Cardiol Therapeutics to post ($0.19) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.

Cardiol Therapeutics Stock Performance

NASDAQ:CRDL opened at $1.03 on Tuesday. Cardiol Therapeutics has a 12-month low of $0.88 and a 12-month high of $2.34. The stock’s fifty day simple moving average is $1.51 and its 200-day simple moving average is $1.30.

Wall Street Analysts Forecast Growth

CRDL has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiol Therapeutics in a report on Monday, September 21st. Canaccord Genuity Group upped their price target on Cardiol Therapeutics from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Cardiol Therapeutics in a research report on Wednesday, September 23rd. Finally, B. Riley Financial assumed coverage on shares of Cardiol Therapeutics in a research note on Wednesday, August 26th. They set a “buy” rating and a $11.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cardiol Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapies for diseases of the heart and other conditions involving inflammation and fibrosis. The company’s research is centered on novel pharmaceutical treatments intended to address unmet needs in cardiovascular medicine.

Cardiol’s lead investigational product, CardiolRx, is an oral formulation of pharmaceutical-grade cannabidiol. It is being evaluated as an anti-inflammatory therapy for acute myocarditis, an inflammation of the heart muscle, and recurrent pericarditis, an inflammation of the membrane surrounding the heart.